Agenda

17.30 - 18.00

Opening Address Special Lecture; Jay Bradner
President of the Novartis Institutes for BioMedical Research (NIBR)

07.45

Meeting Registration

08.00

Introduction & Meeting Objectives
John Gribben

08.15 - 09.45

Session I: T-cell Lymphomas

Chairs: Laurence de Leval & Francine Foss

• Defining vulnerabilities and new targets in peripheral T-cell lymphomas; David Weinstock
• TCR signalling pathway in T-cell lymphomas pathogenesis and implications for therapy; Roberto Chiarle
• Indications of brentuximab vedotin and stem cell transplantation in the management of T-cell lymphomas; Ranjana Advani
• Identification of patients with HTLV1 infection at high risk for progression to ATLL; Lucy Cook

Roundtable Discussion: Laurence de Leval, Francine Foss & Session Speakers

09.45 - 10.30

Special Lecture: 25 years after REAL: Looking back and looking forward

Chairs: John Gribben & Laurence de Leval

• Elaine Jaffe

10.45 - 12.45

Session II: The Tumor Microenvironment in Lymphoma

Chairs: Nathan Fowler 

• Genetics of follicular lymphoma and their impact on the tumor microenvironment; Robert Kridel
• Novel therapies targeting the microenvironment; Nathan Fowler
• Optimizing checkpoint inhibitors; TBC
• Immunomodulatory drugs and the immune microenvironment; TBC

Roundtable Discussion

13.45 - 14.45

Session III: Keynote Address & Special Topic

Chairs: John Gribben

• Genetic bases of immune evasion in lymphoid malignancies; Margaret Shipp

Roundtable Discussion

14.45 - 16.45

Session IV: Immunotherapy of Lymphoma

Chairs: Laurie Sehn & Ranjana Advani

• Targeting lymphocyte checkpoints in NHL; Kerry Savage
• Targeting the macrophage checkpoint in NHL; Ranjana Advani
• Bi-specific antibodies in NHL; Laurie Sehn
• How do we rationally combine immunotherapy approaches and design clinical trials?; Philippe Armand
• Pharmacodynamic markers of immunotherapy approaches – how can we measure benefit?; John Gribben

Roundtable Discussion: Session Speakers

09.00 - 11.00

Session V: Novel Lymphoma Targets/Agents

Chairs: John Gribben & Tom Witzig

• Venetoclax combinations in DLBCL; Sven De Vos
• SYK-JAK inhibitors; Certulatinib update; TBC
• ADC (Polatuzumab) combinations in DLBCL; Laurie Sehn
• Oral PI3K delta (δ) inhibitors in lymphoma; Sven de Vos
• Ibrutinib combinations for NHL; Francisco Hernandez-Illizariturri
• 2nd generation novel BTK inhibitors in lymphoma:
  • Zanubrutinib; Constantine Tam 
  • Acalabrutinib in R/R MCL; Tom Witzig
• SINE inhibitors: Selinexor; Tom Witzig

Roundtable Discussion: Session Speakers

11.15 - 13.30

Session VI: T-Cell Therapies for Lymphoma – CD19-CARs and Beyond

Chairs: Cath Bollard & Dave Maloney

• CD19-CAR-T overview; Dave Maloney
• Factors impacting PFS after CD19 CAR-T cells; Cameron Turtle
• CD20-CAR-T therapy for NHL; Brian Till 
• CD5 and CD7 CAR-T cells; Max Mamonkin
• CD30 CAR-T cells; Barbara Savoldo
• TAA-specific T cells; Cath Bollard

Roundtable Discussion

13.30 - 13.45

Final Meeting Summary & Conclusions
iwNHL Committee